Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

KRAS-Mutated, Estrogen Receptor-Positive Low-Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery

The Oncologist(2021)10.1002/onco.13702Source: DataRank Database

KRAS-Mutated, Estrogen Receptor-Positive Low-Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery is a research paper published in The Oncologist (2021). On theSindex it has a DataRank of 0. It has been cited 14 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access14 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 2.01)OA: hybridTopics (50)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Thomas McFall ORCID,Kenta Takahashi ORCID,Kasey Bamel,Sadakatsu Ikeda ORCID,Ramez N. Eskander ORCID

Live enrichment

PubMed:33528846 PMC:PMC8018312 OpenAlex:https://openalex.org/W3128225985

National Institutes of Health

Grant: P30 CA023100

National Institutes of Health

Grant: K22CA216318

National Institutes of Health

Grant: T32CA009370

National Institutes of Health

Grant: P30CA014195

National Institutes of Health

Grant: 2P30CA014195-31

Senior Leadership

National Institutes of Health

Grant: 3P30CA023100-25S4

Specialized Cancer Center Support Grant

National Institutes of Health

Grant: 1K22CA216318-01

Systems Biology of RAS and RAF Oncogenes and Personalized Medicine

National Institutes of Health

Grant: 5T32CA009370-06

CELL REGULATION DIFFERENTIATION AND CANCER

FWCI

2.01

Citation Percentile

0.9%

Citation Trend

2021

2022

2024

2025

hybridLicense: cc-by-nc-nd

journalhttps://doi.org/10.1002/onco.13702

publisherhttps://doi.org/10.1002/onco.13702

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/onco.13702

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1002/onco.13702

publisherhttps://academic.oup.com/oncolo/article-pdf/26/4/e530/41923680/oncolo_26_4_e530.pdf

Fields of Study

Ovarian cancer diagnosis and treatmentPI3K/AKT/mTOR signaling in cancerEstrogen and related hormone effects03 medical and health sciences0302 clinical medicine

MeSH Terms

FemaleHumansNitrilesOvarian NeoplasmsReceptors, EstrogenTamoxifenTriazolesProto-Oncogene Proteins p21(ras)Phosphatidylinositol 3-KinasesAromatase Inhibitors

Keywords

LetrozoleTrametinibTamoxifenMEK inhibitorMedicineEstrogen receptorAromatase inhibitorKRASCancer researchFulvestrantAromataseOvarian cancerSelective estrogen receptor modulatorPharmacologyInternal medicineBreast cancerOncologyCancerMAPK/ERK pathwayBiologySignal transductionColorectal cancerEstrogenCombinationPersonalized TherapyOvarian NeoplasmsAromatase InhibitorsTriazolesProto-Oncogene Proteins p21(ras)Phosphatidylinositol 3-KinasesReceptors, EstrogenNitrilesHumansPrecision Medicine Clinic: Molecular Tumor BoardFemale

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being